JERSEY CITY, N.J., Aug. 8, 2017 – Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is now available for treatment in the United States. RADICAVA, the first FDA-approved ALS treatment option in more than 20 years,...